Filtered By:
Management: Food and Drug Administration (FDA)

This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 621 results found since Jan 2013.

MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols.
Authors: Lu H, Kashani AH, Arfanakis K, Caprihan A, DeCarli C, Gold BT, Li Y, Maillard P, Satizabal CL, Stables L, Wang DJJ, Corriveau RA, Singh H, Smith EE, Fischl B, van der Kouwe A, Schwab K, Helmer KG, Greenberg SM, MarkVCID Consortium Abstract The MarkVCID consortium was formed under cooperative agreements with the National Institute of Neurologic Diseases and Stroke (NINDS) and National Institute on Aging (NIA) in 2016 with the goals of developing and validating biomarkers for the cerebral small vessel diseases associated with the vascular contributions to cognitive impairment and dementia (VCID). Rigorously ...
Source: The Journal of Alzheimers Association - January 24, 2021 Category: Psychiatry Tags: Alzheimers Dement Source Type: research

FDA clears use of MRI for Impulse Dynamics' Optimizer
The U.S. Food and Drug Administration (FDA) has cleared for conditional use...Read more on AuntMinnie.comRelated Reading: Socioeconomic status predicts heart failure mortality AI predicts heart attack, stroke on cardiac MRI MRI discovers heart damage among male triathletes
Source: AuntMinnie.com Headlines - January 20, 2021 Category: Radiology Source Type: news

Tenecteplase for Acute Ischemic Stroke Treatment
Semin Neurol DOI: 10.1055/s-0040-1722722The introduction of thrombolytic therapy in the 1990s has transformed acute ischemic stroke treatment. Thus far, intravenous recombinant tissue plasminogen activator (rt-PA) also known as alteplase is the only thrombolytic proven to be efficacious and approved by the United States Food and Drug Administration. But the thrombolytic agent tenecteplase (TNK) is emerging as a potential replacement for rt-PA. TNK has greater fibrin specificity, slower clearance, and higher resistance to plasminogen activator inhibitor-1 than rt-PA. Hence, TNK has the potential to provide superior lysis wi...
Source: Seminars in Neurology - January 20, 2021 Category: Neurology Authors: Baird, Alison E. Jackson, Richard Jin, Weijun Tags: Review Article Source Type: research

Inhibiting ferroptosis: A novel approach for stroke therapeutics.
Abstract Stroke ranks as the second leading cause of death across the globe. Despite advances in stroke therapeutics, no US Food and Drug Administration (FDA)-approved drugs that can minimize neuronal injury and restore neurological function are clinically available. Ferroptosis, a regulated iron-dependent form of nonapoptotic cell death, has been shown to contribute to stroke-mediated neuronal damage. Inhibitors of ferroptosis have also been validated in several stroke models of ischemia or intracerebral hemorrhage. Herein, we review the therapeutic activity of inhibitors of ferroptosis in stroke models. We furth...
Source: Drug Discovery Today - January 4, 2021 Category: Drugs & Pharmacology Authors: Jin Y, Zhuang Y, Liu M, Che J, Dong X Tags: Drug Discov Today Source Type: research

Psychostimulant use disorder emphasizing methamphetamine and the opioid -dopamine connection: Digging out of a hypodopaminergic ditch
Approved food and drug administration (FDA) medications to treat Psychostimulant Use Disorder (PUD) are needed. Both acute and chronic neurological deficits related to the neurophysiological effects of these powerfully addictive drugs can cause stroke and alterations in mood and cognition.
Source: Journal of the Neurological Sciences - November 27, 2020 Category: Neurology Authors: Kenneth Blum, Jean Lud Cadet, Mark S. Gold Tags: Review Article Source Type: research

Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices.
Abstract Balancing benefits and risks is a complex task that poses a major challenge, both to the approval of new medicines and devices by regulatory authorities and in therapeutic decision-making in practice. Several analysis methods and visualization tools have been developed to help evaluate and communicate whether the benefit-risk profile is favorable or unfavorable. In this White Paper, we describe approaches to benefit-risk assessment using qualitative approaches such as the Benefit Risk Action Team framework developed by the Pharmaceutical Research and Manufacturers of America, and the Benefit-Risk Framewor...
Source: Circulation - November 17, 2020 Category: Cardiology Authors: Kaul S, Stockbridge N, Butler J Tags: Circulation Source Type: research

Study: Fish Oil Doesn ’ t Seem To Prevent Heart Problems
This study is consistent with earlier trials. The US Food and Drug Administration approved the fish oil-based drug Vascepa for heart attack and stroke prevention in 2019. Nissen hopes the FDA will take a look at these studies and reconsider that decision. “But it’s hard to get something undone once the genie gets out of the bottle,” he said. An editorial in the journal that accompanies the study written by Dr. Gregory Curfman, assistant professor of medicine at Harvard Medical School, also suggested the FDA should require a postmarketing clinical trial of a high-dose of fish oil, such as Vascepa, vs. corn...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 16, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Health Syndicated CBSN Boston CNN fish oil Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Stroke Risk Among Elderly Users of Haloperidol and Typical Antipsychotics Versus Atypical Antipsychotics: A Real-World Study From a US Health Insurance Claims Database
Antipsychotics are approved and prescribed to treat various conditions such as schizophrenia, mania, major depressive disorder, agitation, delusional disorder, psychosis, and Tourette's syndrome.1 The haloperidol prescribing information2 in the United States (US) does not warn about the risk of stroke but has a black box warning for an increased risk of death among elderly patients with dementia-related psychosis treated with antipsychotic drugs. Nonetheless, antipsychotics are used for indications such as neuropsychiatric symptoms of dementia, in the presence or absence of psychosis; such use is not approved by the Food a...
Source: The American Journal of Geriatric Psychiatry - September 26, 2020 Category: Geriatrics Authors: Daniel Fife, Clair Blacketer, R. Karl Knight, James Weaver Tags: Regular Research Article Source Type: research

Stroke Risk among Elderly Users of Haloperidol and Typical Antipsychotics vs. Atypical Antipsychotics: A Real-World Study from a US Health Insurance Claims Database
Antipsychotics are approved and prescribed to treat various conditions such as schizophrenia, mania, major depressive disorder, agitation, delusional disorder, psychosis, and Tourette's syndrome1. The haloperidol prescribing information2 in the United States (US) does not warn about the risk of stroke but has a black box warning for an increased risk of death among elderly patients with dementia-related psychosis treated with antipsychotic drugs. Nonetheless, antipsychotics are used for indications such as neuropsychiatric symptoms of dementia, in the presence or absence of psychosis; such use is not approved by the Food a...
Source: The American Journal of Geriatric Psychiatry - September 25, 2020 Category: Geriatrics Authors: Daniel Fife, Clair Blacketer, R. Karl Knight, James Weaver Source Type: research

We Need a COVID-19 Vaccine. We Also Need Transparency About Its Development
The authorization of an effective vaccine will mark perhaps the biggest turning point in the battle against coronavirus, but only if enough people are willing to get vaccinated. There have been substantial declines in public willingness to get vaccinated against COVID-19, despite immense, unprecedented public investments in vaccine development. In one survey, barely half of Americans said they would get the vaccine as soon as it was available, numbers that will undermine the benefits of even a highly effective vaccine. It is no mystery why trust in a potential vaccine has plummeted. Operation Warp Speed, the Trump Administ...
Source: TIME: Health - September 18, 2020 Category: Consumer Health News Authors: Dr. Ashish K. Jha Tags: Uncategorized COVID-19 Source Type: news

Monoclonal antibody as an emerging therapy for acute ischemic stroke.
Authors: Woods D, Jiang Q, Chu XP Abstract Acute ischemic stroke (AIS) is the 5th leading cause of death and the leading cause of neurological disability in the United States. The oxygen and glucose deprivation associated with AIS not only leads to neuronal cell death, but also increases the inflammatory response, therefore decreasing the functional outcome of the brain. The only pharmacological intervention approved by the US Federal Food and Drug Administration for treatment of AIS is tissue plasminogen activator (t-PA), however, such treatment can only be given within 4.5 hours of the onset of stroke-like sympto...
Source: International Journal of Physiology, Pathophysiology and Pharmacology - September 18, 2020 Category: Physiology Tags: Int J Physiol Pathophysiol Pharmacol Source Type: research

New Treatment for Lou Gehrig ' s Disease Shows Promise
A study of their therapy and clinical trials of other experimental treatments are offering glimmers of hope that paralysis from the disorder can be slowed.
Source: NYT Health - September 2, 2020 Category: Consumer Health News Authors: Pam Belluck Tags: Amyotrophic Lateral Sclerosis Clinical Trials Research Drugs (Pharmaceuticals) ALS Assn Food and Drug Administration National Institute of Neurological Disorders and Stroke New England Journal of Medicine Koroshetz, Walter J your-feed-he Source Type: news

The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Authors: Trivedi K, Le V, Nelson JR Abstract The high-purity eicosapentaenoic acid (EPA) prescription fish oil-derived omega-3 fatty acid (omega-3), icosapent ethyl (IPE), was recently approved by the United States Food and Drug Administration (FDA) for cardiovascular disease (CVD) prevention in high-risk patients. This approval is based on the 25% CVD event risk reduction observed with IPE in the pre-specified primary composite endpoint (cardiovascular [CV] death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina) in the landmark Reduction of Cardio...
Source: Postgraduate Medicine - August 13, 2020 Category: Internal Medicine Tags: Postgrad Med Source Type: research